Becker, M A <br/><br/>
Diabetes and gout: efficacy and safety of febuxostat and allopurinol.  [electronic resource] 

 -  Diabetes, obesity & metabolism  Nov 2013 
 - 1049-55 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1463-1326 
<br/><br/><label>Standard No.: </label>10.1111/dom.12135  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Allopurinol--administration & dosage<br/>Body Mass Index<br/>Cohort Studies<br/>Comorbidity<br/>Diabetes Complications--blood<br/>Dose-Response Relationship, Drug<br/>Enzyme Inhibitors--administration & dosage<br/>Febuxostat<br/>Female<br/>Gout--blood<br/>Gout Suppressants--administration & dosage<br/>Humans<br/>Intention to Treat Analysis<br/>Kidney--physiopathology<br/>Lost to Follow-Up<br/>Male<br/>Middle Aged<br/>Obesity--epidemiology<br/>Patient Dropouts<br/>Renal Insufficiency--epidemiology<br/>Thiazoles--administration & dosage<br/>Xanthine Oxidase--antagonists & inhibitors<br/>Young Adult